(Total Views: 582)
Posted On: 01/10/2021 4:42:38 PM
Post# of 154098
Thanks for posting the response.
“What I’m saying is the lab data with the secondary endpoints chosen would clearly indicate to the expert eye who received LL and who didn’t.”
Bottom Line: Even if CYDY has seen the blinded bilirubin and platelet data, there’s no known correlation between decreased bilirubin/increased platelet levels and increased survivability rate in the COVID S/C population. No expert could simply say leronlimab is working of these two labs. If this were true, MM and the rest of CYDY would be buying shares non-stop.
“What I’m saying is the lab data with the secondary endpoints chosen would clearly indicate to the expert eye who received LL and who didn’t.”
Bottom Line: Even if CYDY has seen the blinded bilirubin and platelet data, there’s no known correlation between decreased bilirubin/increased platelet levels and increased survivability rate in the COVID S/C population. No expert could simply say leronlimab is working of these two labs. If this were true, MM and the rest of CYDY would be buying shares non-stop.
(2)
(4)
